BioSpace News Archive

The current Ebola outbreak in the Democratic Republic of the Congo is nearing its one-year anniversary.

Invitae Corporation, a leading medical genetics company, announced that it granted time-based and development milestone-based restricted stock units to new employees who joined Invitae in connection with its acquisition of Singular Bio, Inc.

T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, will share multiple updates regarding the clinical utility of its expanding portfolio of groundbreaking rapid diagnostics and technology during ASM Microbe 2019 in San Francisco, CA from June 19 to 24.

Metabolic or bariatric surgery was significantly more effective than medical management in treating type 2 diabetes in patients with milder forms of obesity, according to new research presented here at an American Society for Metabolic and Bariatric Surgery (ASMBS) national clinical symposium on obesity prevention, treatment and research.

Women Who Tech, one of the largest nonprofit organizations that funds and showcases women-led ventures, today opened the call for applications for the European-leg of its flagship Women Startup Challenge.

Patients with severe obesity who get weight-loss surgery cut their spending on diabetes medications by nearly 65 percent and spending on high blood pressure medications by more than a third three to six months after the operation, according to new research from Rush Medical College in Chicago presented here at an American Society for Metabolic and Bariatric Surgery

Agendia, Inc. a world leader in precision oncology, announced today the open access publication of MammaPrint and BluePrint Molecular Diagnostics using targeted RNA Next-Generation Sequencing technology in the Journal of Molecular Diagnostics.

IDDI’s findings suggest that it is appropriate to use disease-free survival (DFS) as a surrogate for overall survival (OS) in trials in HER-2-positive, early breast cancer.

Thermo Fisher Scientific has developed a new line of next-generation open air orbital shakers to offer unmatched reliability and superior user programmability in a compact benchtop design.

BioAscent Discovery Limited (www.bioascent.com) has announced a three-fold increase in revenues during 2018, with projections on-track for a further 2.5-fold increase in 2019.